Vivus stock suffers on likely EU rejection; Watson recalls painkiller on potency worries;

 @FiercePharma: U.K.'s Rosemont Pharmaceuticals is up for sale. Value est. at £200M; specializes in liquid formulations--Sky News. Report | Follow @FiercePharma

> Vivus ($VVUS) stock is on the slide after the company announced it expects its new weight-loss drug to be rejected by European regulators in October. Report

> Watson Pharmaceuticals ($WPI) recalled two lots of its hydrocodone and acetaminophen painkiller because of the possibility that the pills may be more potent than intended. Report

> Valeant Pharmaceuticals ($VRX) paid $62.5 million to buy the U.S. rights to Visudyne, a treatment for age-related vision loss, from developer QLT. Report

> Ireland's Elan tapped Hans Peter Hasler as its incoming chief operating officer, as of Oct. 1; he is currently a non-executive director on the company's board. Report

> Canadian health advocates protested provisions of a free trade deal between Canada and the EU, saying they will hike drug costs and benefit Big Pharma. Report

Medical Device News

 @FierceMedDev: Tribogenics pulled in a $6.2M Series A round, to help develop portable X-ray sources for medical imaging. Release | Follow @FierceMedDev

 @MarkHFierce: Look at Teleflex, getting a 510(k) for a continuous peripheral nerve block catheter--a new anesthesia tool. Release | Follow @MarkHFierce

 @DamianFierce: Medtronic is making noise in India, appointing a new board member and committing $6M in grant money there. More | Follow @DamianFierce

> Boston Sci rolls out fresh cardiac products for two international launches. Story

> South Korea's SK Telecom dives into China's medtech industry. Item

Biotech News

 @FierceBiotech: In case you missed it last week, check out our 2012 Fierce 15 report: Report | BPA 2012 Slideshow | Follow @FierceBiotech

 @JohnCFierce: Peregrine is now a penny stock company, down 85%. And somewhere lawyers are beginning a new day, aflutter with litigious thoughts. | Follow @JohnCFierce

 @RyanMFierce: Virtual R&D groups make sense in cases where a pharma might otherwise just pull the plug on R&D in a field like CNS. More | Follow @RyanMFierce

> Mallinckrodt swallows CNS Therapeutics' drug pipeline in $100M buyout. News

> Novo Nordisk boosts China R&D with $100M diabetes research project. Report

> Peregrine shares blasted after trial 'discrepancies' discredit lung cancer data. Article

CRO News

> EU experts call for clinical trials to focus on the elderly. Report

> Big Pharmas unite to improve clinical development. Article

> CMOs move toward disposable manufacturing tech. More

> Covance taps big data outfit for diabetes R&D. Story

Biotech IT News

> Google VC unit angles for further life sciences investments. Article

> NYC startup Medikly caters to pharma interactions with docs. More

> Accelrys goes late-stage in R&D software game. Story

> AstraZeneca builds virtual neuroscience drug unit byte by byte. Report

And Finally... A new study identified genetically distinct types of breast cancer and the genetic changes that are their hallmarks. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.